Please login to the form below

Not currently logged in
Email:
Password:

Onyx Pharma appoints John Osborn SVP global corporate affairs

Joins from Dendreon to lead public and government affairs activities

Dendreon's John Osborn has joined Onyx Pharmaceuticals as senior VP, global corporate affairs.

In his new role at the US-based biopharma, he will lead the company's public and government affairs activities, as well as key stakeholder relationships.

Osborn's most recent position was executive VP, general counsel and secretary at Dendreon, which markets cancer vaccine Provenge.

Prior to his time at Dendreon, he held similar roles at US Oncology and Cephalon.

He also spent time serving with the US Department of State and was a member of the bipartisan United States Advisory Commission on Public Diplomacy in 2008.

“As a lawyer, policy advocate and former diplomat, John brings a diverse and extensive background to Onyx, with broad experience across the life sciences industry and the US government,” said Dr Anthony Coles, president and CEO of Onyx.

“John is a proven leader and his unique expertise aligns well with our plan for global growth as a multi-product company reaching patients around the world.”

20th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics